Huy Hoang
Optometrist · Seattle, WANPI 1932323813
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 371 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 24.9% of the total. Among optometrist clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 371 payments — averaging $30.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$3K
- Bausch & Lomb Americas Inc.$2K
- Sun Pharmaceutical Industries Inc.$1K
- AbbVie$1K
- Johnson & Johnson Vision Care, Inc.$822
- Alcon$631
- plus $3K from 18 others
What the payments were for
- Food & beverage$11,430100%
- Gifts$370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 91 | $2,851 |
| Bausch & Lomb Americas Inc. | 47 | $1,567 |
| Sun Pharmaceutical Industries Inc. | 36 | $1,235 |
| AbbVie(2 entities) | 45 | $1,037 |
| Johnson & Johnson Vision Care, Inc. | 46 | $822 |
| Alcon | 13 | $631 |
| Mallinckrodt Enterprises LLC | 16 | $458 |
| Dompe US, Inc. | 14 | $410 |
| Oyster Point Pharma, Inc. | 9 | $398 |
| Tarsus Pharmaceuticals, Inc. | 6 | $372 |
| Novartis | 16 | $299 |
| Eyevance Pharmaceuticals LLC | 2 | $286 |
| Biotissue Holdings Inc. | 4 | $222 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $219 |
| ANI Pharmaceuticals, Inc. | 4 | $188 |
| Glaukos Corporation | 1 | $169 |
| Kala Pharmaceuticals, Inc. | 2 | $132 |
| Katena Products, Inc. (dba Corza Medical) | 2 | $55 |
| LKC Technologies, Inc. | 1 | $23 |
| Coopervision Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Thea Pharma Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$1,305
- MIEBO$521
- CEQUA$469
- XIIDRA$399
- LUMIGAN$343
- INFUSE$296
- XDEMVY$275
- Flarex$273
- DURYSTA$218
- XEN GLAUCOMA TREATMENT SYSTEM$218
- Photrexa Viscous and Photrexa$169
- Acuvue$161
- TYRVAYA$149
- Clareon$143
- Clareon PanOptix Pro$140
- PURIFIED CORTROPHIN GEL$127
- Oxervate$126
- EYSUVIS$106
How this compares
$11,467 in reported general payments places this provider in the 95th percentile of 1,267 optometrist providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 19 | $1,715,066 |
| RestasisCyclosporine | 1,378 | $1,226,825 |
| XiidraLifitegrast | 644 | $694,449 |
| Lotemax SmLoteprednol Etabonate | 373 | $107,503 |
| LumiganBimatoprost | 216 | $97,394 |
| TyrvayaVarenicline Tartrate | 33 | $23,421 |
| Cyclosporine | 87 | $23,396 |
| FlarexFluorometholone Acetate | 107 | $16,843 |
| CequaCyclosporine | 13 | $13,556 |
| Loteprednol Etabonate | 79 | $12,202 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $8,495 |
| Fluorometholone | 91 | $7,430 |
| LotemaxLoteprednol Etabonate | 20 | $6,862 |
| VyzultaLatanoprostene Bunod | 15 | $6,323 |
| ErythromycinErythromycin Base | 387 | $5,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $2,851 | $1,715,06619 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,037 | $1,335,8131,632 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $1,567 | $700,773659 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate, Lotemax | $219 | $126,567472 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $398 | $23,42133 claims |
| Eyevance Pharmaceuticals LLCFlarex | $286 | $16,843107 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,235 | $13,55613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,267 optometrist providers in Washington.
Other optometrist in Seattle
- Roya HabibiSeattle$109K
- Anita LamSeattle$30K
- Jemimah CorpuzSeattle$8K
- Sathi MaitiSeattle$7K
- Leslie LungSeattle$7K
- Gregory ChinSeattle$6K
- Leigh KimSeattle$6K
- Steve BirdSeattle$5K
- Kerri SvandaSeattle$5K
- David KadingKirkland$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.